JPH07509218A - エストロゲン/プロゲスチン/アンチプロゲスチン方法並びに経口避妊及び月経調整のためのキット - Google Patents
エストロゲン/プロゲスチン/アンチプロゲスチン方法並びに経口避妊及び月経調整のためのキットInfo
- Publication number
- JPH07509218A JPH07509218A JP5515869A JP51586993A JPH07509218A JP H07509218 A JPH07509218 A JP H07509218A JP 5515869 A JP5515869 A JP 5515869A JP 51586993 A JP51586993 A JP 51586993A JP H07509218 A JPH07509218 A JP H07509218A
- Authority
- JP
- Japan
- Prior art keywords
- estrogen
- progestin
- antiprogestin
- menstruation
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (22)
- 1.現状打破性出血及び投薬中止無月経の発生を惹起するのに十分な低さの投与 量のエストロゲンを雌の哺乳動物に投与することに関係する出血の問題を回避す る方法において、該雌に現状打破性出血の減少もしくは排除に有効であリ、かつ 場合によっては、月経を誘発するための、蓄積された子宮内膜組織の腐肉形成の 誘発にも有効である量のアンチプロゲスチンを定期的に投与することを特徴とす る方法。
- 2.雌の哺乳動物が、避妊を要求する人間の生殖腺であリ、エストロゲンをプロ ゲスチンとの組合せ物の形で、卵胞発生の遮断に有効である量で投与し、かつこ のことによって該生殖腺に避妊状態を惹起しかつアンチプロゲスチンの投与によ って月経を誘発する、請求項1記載の方法。
- 3.アンチプロゲスチンをほぼ月1回投与する、請求項1記載の方法。
- 4.雌が、ホルモン置換治療を受けている閉経期後の女性である、請求項1記載 の方法。
- 5.エストロゲンをプロゲスチンとの組合せ物の形で、子宮内膜増殖の抑制に有 効である量で投与する、請求項2記載の方法。
- 6.アンチプロゲスチンを1か月よリ長い間隔をおいて投与する、請求項1記載 の方法。
- 7.プロゲスチン及びエストロゲンの投与を、月経期間中を含めて周期を通して 中断せずに続行する、請求項2記載の方法。
- 8.プロゲスチン及びエストロゲンの投与をアンチプロゲスチン投与直前に中断 する、請求項1記載の方法。
- 9.アンチプロゲスチンを経口投与する、請求項1記載の方法。
- 10.アンチプロゲスチンがミテブリストンである、請求項1記載の方法。
- 11.エストロゲンがエチニルエストラジオールである、請求項1記載の方法。
- 12.プロゲスチンがノルエチンドロンアセテートである、請求項1記載の方法 。
- 13.雌の哺乳動物が、人間の生殖腺であリ、エストロゲンとプロゲスチンの投 与量が、卵胞発生の遮断に有効であリ、かつこのことによって該生殖腺に避妊状 態を惹起し;アンチプロゲスチンを経口投与し;かつその際、プロゲスチン及び エストロゲンの投与を、月経期間中も含めて周期を通して中断せずに続行する、 請求項1記載の方法。
- 14.アンチプロゲスチンをほぼ月1回投与する、請求項12記載の方法。
- 15.アンチプロゲスチンを1か月よリ長い間隔をおいて投与する、請求項12 記載の方法。
- 16.エストロゲン及びプロゲスチンを含有する錠剤少なくとも約20個を含有 するキットにおいて、該錠剤が、該錠剤21個が連続した数日間で服用される場 合には人間の女性の生殖腺の場合には連続的な経口避妊を達成するのに集合的に 有効であるが、しかし、月経を誘発するために該錠剤の投与が各1か月の周期中 に1週間中断される場合にの、現状打破性出血の発生を回避するには低すぎる量 のエストロゲン及びプロゲスチンを含有しておリ;かつ、月経を誘発するのに有 効な量のアンチプロゲスチンを含有している錠剤を、エストロゲン及びプロゲス チンを含有する錠剤少なくとも20個が服用された後に服用されるべくキットに 配置された状態で含有していることを特徴とする、キット。
- 17.第20錠剤もしくはそれ以降の順番の錠剤として位置されたアンチプロゲ スチンを含有している錠剤と一緒に、逐次的に服用されるために配置されたエス トロゲン及びプロゲスチンを含有している錠剤28個を含有している、請求項1 5記載のキット。
- 18.エストロゲンがエチニルエストラジオールであリ、プロゲスチンがノルエ チンドロンアセテートであリ、かつアンチプロゲスチンがミフェプリストンであ る、請求項15記載のキット。
- 19.エストロゲンがエチニルエストラジオールであリ、プロゲスチンがゲスト デンであリ、かつアンチプロゲスチンがオナブリストンである、請求項15記載 のキット。
- 20.固体経口単位投薬形態での医薬品において、避妊に関してそれぞれエチニ ルエストラジオール5mcg.〜35mcg.及びノルエチンジオールアセテー ト0.5mg.〜1.5mg.に等量である量のエストロゲン及びプロゲスチン 並びに、相応する量のエストロゲン及びプロゲスチンを少なくとも20日間毎日 摂取した人間の女性の場合に月経を誘発するのに有効である量のアンチプロゲス チンを含有していることを特徴とする、医薬品。
- 21.エチニルエストラジオール0.5〜35mcg.、ノルエチンドロンアセ テート0.5〜35mg及びミフェプリストン50〜500mg.を含有してい る、請求項19記載の医薬品。
- 22.エチニルエストラジオール0.5〜35mcg.、ゲストデン10〜15 mcg.及びオナプリストン50〜500mg.を含有している、請求項19記 載の医薬品。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84305892A | 1992-03-02 | 1992-03-02 | |
US843,058 | 1992-03-02 | ||
PCT/US1993/001931 WO1993017686A1 (en) | 1992-03-02 | 1993-03-02 | Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses |
CN93102182A CN1090481C (zh) | 1992-03-02 | 1993-03-02 | 雌激素/孕激素/抗孕激素的应用,其组合物和药盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07509218A true JPH07509218A (ja) | 1995-10-12 |
JP4152431B2 JP4152431B2 (ja) | 2008-09-17 |
Family
ID=25743002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51586993A Expired - Fee Related JP4152431B2 (ja) | 1992-03-02 | 1993-03-02 | エストロゲン/プロゲスチン/アンチプロゲスチン方法並びに経口避妊及び月経調整のためのキット |
Country Status (16)
Country | Link |
---|---|
US (1) | US7538099B1 (ja) |
EP (1) | EP0630246B1 (ja) |
JP (1) | JP4152431B2 (ja) |
CN (1) | CN1090481C (ja) |
AU (1) | AU678150B2 (ja) |
BR (1) | BR9306005A (ja) |
CZ (1) | CZ291988B6 (ja) |
FI (1) | FI110307B (ja) |
IL (1) | IL104915A (ja) |
MX (1) | MX9301121A (ja) |
NO (1) | NO311327B1 (ja) |
NZ (1) | NZ268304A (ja) |
PL (2) | PL172790B1 (ja) |
SK (1) | SK285963B6 (ja) |
WO (1) | WO1993017686A1 (ja) |
ZA (1) | ZA931492B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018515552A (ja) * | 2015-05-18 | 2018-06-14 | アジル・セラピューティクス・インコーポレイテッドAgile Therapeutics, Inc. | 避妊用組成物ならびに有効性改善および副作用調節方法 |
US10308676B2 (en) | 2015-09-25 | 2019-06-04 | Context Biopharma Inc. | Methods of making onapristone intermediates |
US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
US10786461B2 (en) | 2014-11-17 | 2020-09-29 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
US11613555B2 (en) | 2016-11-30 | 2023-03-28 | Context Biopharma, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
US5521166A (en) * | 1994-12-19 | 1996-05-28 | Ortho Pharmaceitical Corporation | Antiprogestin cyclophasic hormonal regimen |
DE19531936A1 (de) * | 1995-08-17 | 1997-02-20 | Schering Ag | Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend |
US5898032A (en) | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
AU747710B2 (en) | 1997-11-14 | 2002-05-23 | Akzo Nobel N.V. | Progestogen-antiprogestogen regimens |
US6020328A (en) * | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US5962444A (en) * | 1998-05-29 | 1999-10-05 | Research Triangle Institute | 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
US6262042B1 (en) | 1998-05-29 | 2001-07-17 | Research Triangle Institute | 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
NZ514895A (en) * | 1999-04-29 | 2004-06-25 | Akzo Nobel Nv | Use of the anti-progestagen ORG 33245 administrated intermittently with a daily dosage of a progestagen in combined therapy |
EE200200102A (et) * | 1999-08-31 | 2003-04-15 | Jenapharm Gmbh & Co. Kg | Mesoprogestiinid (progesterooniretseptori modulaatorid) hormoonasendusravi (HAR) kompositsioonide komponendina |
SI1453521T1 (sl) | 2001-12-05 | 2013-11-29 | Teva Women's Health, Inc. | Oralni kontraceptiki za preprečevanje nosečnosti in zmanjševanje predmenstrualne simptomatike |
EP1624848A4 (en) | 2003-05-02 | 2009-02-25 | Duramed Pharmaceuticals Inc | METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE |
CA2771944A1 (en) * | 2003-07-16 | 2005-01-27 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
HRP20211377T1 (hr) | 2011-11-23 | 2022-01-07 | Therapeuticsmd, Inc. | Prirodne kombinirane hormonske supstitucijske formulacije i terapije |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9603856B2 (en) * | 2013-11-03 | 2017-03-28 | Flamina Holding Ag | Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2951284A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3890356A (en) | 1973-03-26 | 1975-06-17 | Richardson Merrell Inc | 7-Alkyl-{66 {hu 3,5{b -steroids |
US3928398A (en) | 1973-11-01 | 1975-12-23 | Richardson Merrell Inc | Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol |
US4018919A (en) * | 1975-07-16 | 1977-04-19 | Eli Lilly And Company | Sequential contraceptive method using two types of progestational agents |
US4416822A (en) | 1982-07-09 | 1983-11-22 | The Upjohn Company | 17β-Difluoromethyl steroids |
IL68222A (en) | 1983-03-24 | 1987-02-27 | Yeda Res & Dev | Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity |
ES8502612A1 (es) * | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
US4780461A (en) | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
AU572589B2 (en) | 1983-12-14 | 1988-05-12 | Upjohn Company, The | 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids |
DK174724B1 (da) * | 1986-07-15 | 2003-10-06 | Wyeth Corp | Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet |
DE3702383A1 (de) | 1987-01-23 | 1988-08-04 | Schering Ag | 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
US5116818A (en) | 1987-03-10 | 1992-05-26 | Medical College Of Hampton Roads | Method and kit for contraception with GnRH-antagonist |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
US5439913A (en) | 1992-05-12 | 1995-08-08 | Schering Aktiengesellschaft | Contraception method using competitive progesterone antagonists and novel compounds useful therein |
US5622943A (en) | 1992-05-06 | 1997-04-22 | The Medical College Of Hampton Roads | Minimizing progestin associated breakthrough bleeding |
AU1918092A (en) | 1992-05-06 | 1993-11-29 | Medical College Of Hampton Roads, The | Minimizing progestin associated breakthrough bleeding |
US5516769A (en) | 1993-02-19 | 1996-05-14 | The Medical College Of Hampton Roads | Method of inhibiting fertilization |
US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
DE4344463A1 (de) | 1993-12-22 | 1995-06-29 | Schering Ag | Kombinationsprodukt zur Kontrazeption |
-
1993
- 1993-03-01 MX MX9301121A patent/MX9301121A/es active IP Right Grant
- 1993-03-02 BR BR9306005A patent/BR9306005A/pt not_active Application Discontinuation
- 1993-03-02 PL PL93316357A patent/PL172790B1/pl not_active IP Right Cessation
- 1993-03-02 NZ NZ268304A patent/NZ268304A/en not_active IP Right Cessation
- 1993-03-02 PL PL93304807A patent/PL174785B1/pl not_active IP Right Cessation
- 1993-03-02 SK SK1046-94A patent/SK285963B6/sk unknown
- 1993-03-02 AU AU37879/93A patent/AU678150B2/en not_active Ceased
- 1993-03-02 WO PCT/US1993/001931 patent/WO1993017686A1/en active IP Right Grant
- 1993-03-02 EP EP93907185A patent/EP0630246B1/en not_active Expired - Lifetime
- 1993-03-02 ZA ZA931492A patent/ZA931492B/xx unknown
- 1993-03-02 CN CN93102182A patent/CN1090481C/zh not_active Expired - Fee Related
- 1993-03-02 IL IL10491593A patent/IL104915A/en not_active IP Right Cessation
- 1993-03-02 JP JP51586993A patent/JP4152431B2/ja not_active Expired - Fee Related
-
1994
- 1994-09-01 CZ CZ19942111A patent/CZ291988B6/cs not_active IP Right Cessation
- 1994-09-01 FI FI944022A patent/FI110307B/fi active
- 1994-09-01 NO NO19943234A patent/NO311327B1/no unknown
-
1995
- 1995-06-05 US US08/462,703 patent/US7538099B1/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10786461B2 (en) | 2014-11-17 | 2020-09-29 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
US11672762B2 (en) | 2014-11-17 | 2023-06-13 | Context Biopharma, Inc. | Onapristone extended-release compositions and methods |
JP2018515552A (ja) * | 2015-05-18 | 2018-06-14 | アジル・セラピューティクス・インコーポレイテッドAgile Therapeutics, Inc. | 避妊用組成物ならびに有効性改善および副作用調節方法 |
US10308676B2 (en) | 2015-09-25 | 2019-06-04 | Context Biopharma Inc. | Methods of making onapristone intermediates |
US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
US11613555B2 (en) | 2016-11-30 | 2023-03-28 | Context Biopharma, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Also Published As
Publication number | Publication date |
---|---|
WO1993017686A1 (en) | 1993-09-16 |
NO943234D0 (no) | 1994-09-01 |
PL174785B1 (pl) | 1998-09-30 |
AU3787993A (en) | 1993-10-05 |
US7538099B1 (en) | 2009-05-26 |
EP0630246B1 (en) | 2008-07-16 |
AU678150B2 (en) | 1997-05-22 |
ZA931492B (en) | 1993-12-23 |
EP0630246A4 (en) | 2002-07-17 |
SK285963B6 (sk) | 2007-12-06 |
JP4152431B2 (ja) | 2008-09-17 |
CN1090481C (zh) | 2002-09-11 |
PL172790B1 (pl) | 1997-11-28 |
IL104915A0 (en) | 1993-07-08 |
BR9306005A (pt) | 1998-06-23 |
NO311327B1 (no) | 2001-11-19 |
FI944022A0 (fi) | 1994-09-01 |
FI944022A (fi) | 1994-09-01 |
MX9301121A (es) | 1993-09-01 |
FI110307B (fi) | 2002-12-31 |
CN1079386A (zh) | 1993-12-15 |
SK104694A3 (en) | 1996-01-10 |
CZ211194A3 (en) | 1995-12-13 |
NZ268304A (en) | 1997-02-24 |
IL104915A (en) | 1998-07-15 |
CZ291988B6 (cs) | 2003-07-16 |
EP0630246A1 (en) | 1994-12-28 |
NO943234L (no) | 1994-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH07509218A (ja) | エストロゲン/プロゲスチン/アンチプロゲスチン方法並びに経口避妊及び月経調整のためのキット | |
US5108995A (en) | Hormone preparation and method | |
US5382573A (en) | Hormone preparation and method | |
AU630334B2 (en) | Hormone preparations for hormone replacement therapy and contraceptive method | |
EP0253607B2 (en) | Combination dosage form for premenopausal women | |
RU2169567C2 (ru) | Способ контрацепции женщин репродуктивного возраста, не достигших предменопаузы | |
US5256421A (en) | Hormone preparation and method | |
US7704983B1 (en) | Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception | |
Killick et al. | Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel: effects of low estrogen doses during the hormone-free interval | |
JPH11508538A (ja) | ホルモン避妊用薬剤の複合調剤、キット及び避妊方法 | |
CA2134961C (en) | Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses | |
CA1332227C (en) | Oral contraceptive formulation | |
KR100271750B1 (ko) | 경구 피임 및 월경 조절을 위한 에스트로겐/프로게스틴/안티프로게스틴 방법 및 키트 | |
CA1332228C (en) | Formulation and method for estrogen replacement therapy | |
Wright | Polycystic ovary syndrome | |
IE84449B1 (en) | Contraceptive packages containing oestrogen and progestin | |
IE83631B1 (en) | Hormone preparation and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040303 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061114 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070105 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070326 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070620 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080508 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080702 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110711 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110711 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120711 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |